Free tool
Oncology stocks
We cover 142 companies grouped under the Oncology theme. The median market value in the group is $36.66M. Across the group, the median move over the past trading day is −0.19%. 36% of the 138 with a 200-day average trade above it. Price change over the past year runs from −77.9% to +153.7% across the middle 80 percent of the group, with a median of −24.6%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
142 of 319 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| AZN.L | AstraZeneca PLC | $264.05B | Mega cap | +5.65% |
| AZN | AstraZeneca PLC | $263.12B | Mega cap | +5.09% |
| A1ZN34.SA | AstraZeneca PLC | $258.63B | Mega cap | +0.13% |
| NUVL | Nuvalent Inc | $9.79B | Mid cap | +62.83% |
| 4528.T | Ono Pharmaceutical Co., Ltd. | $7.39B | Mid cap | +54.43% |
| CGON | CG Oncology, Inc. | $6.95B | Mid cap | +196.15% |
| ERAS | Erasca, Inc. | $6.70B | Mid cap | +1112.03% |
| E2XE34.SA | Exelixis, Inc. | $6.61B | Mid cap | +23.92% |
| LNTH | Lantheus Holdings, Inc. | $6.58B | Mid cap | +77.38% |
| COGT | Cogent Biosciences, Inc. | $6.39B | Mid cap | +196.85% |
| CELC | Celcuity Inc. | $4.65B | Mid cap | +90.31% |
| 000100.KS | Yuhan Corporation | $4.50B | Mid cap | −27.54% |
| ELVN | Enliven Therapeutics, Inc. | $4.46B | Mid cap | +194.32% |
| TNGX | Tango Therapeutics, Inc. | $4.29B | Mid cap | +269.13% |
| RLAY | Relay Therapeutics, Inc. | $4.26B | Mid cap | +445.10% |
| RCUS | Arcus Biosciences, Inc. | $3.92B | Mid cap | +191.29% |
| 000105.KS | Yuhan Corporation | $3.84B | Mid cap | −32.04% |
| TLX.AX | Telix Pharmaceuticals Limited | $3.82B | Mid cap | +4.88% |
| TLX | Telix Pharmaceuticals Limited | $3.77B | Mid cap | −8.02% |
| IMNM | Immunome, Inc. | $3.34B | Mid cap | +188.94% |
| SLS | SELLAS Life Sciences Group, Inc. | $2.77B | Mid cap | +615.10% |
| NRIX | Nurix Therapeutics, Inc. | $2.77B | Mid cap | +179.69% |
| NUVB | Nuvation Bio Inc. | $2.44B | Mid cap | +135.93% |
| NBTX | Nanobiotix S.A. | $2.26B | Mid cap | +394.99% |
| URGN | UroGen Pharma Ltd. | $2.25B | Mid cap | +135.11% |
| HCM.L | HUTCHMED (China) Limited | $2.16B | Mid cap | −18.08% |
| HCM | HUTCHMED (China) Limited | $2.15B | Mid cap | −17.45% |
| NVCR | NovoCure Limited | $2.08B | Mid cap | +50.21% |
| NANO.PA | Nanobiotix S.A. | $2.05B | Mid cap | +358.21% |
| JATT | JATT II Acquisition Corp. | $93.68M | Micro cap | +14.38% |
| ACRV | Acrivon Therapeutics, Inc. | $93.42M | Micro cap | +52.94% |
| 4579.T | RaQualia Pharma Inc. | $93.23M | Micro cap | +3.46% |
| OSE.PA | OSE Immunotherapeutics SA | $88.75M | Micro cap | −47.94% |
| MAIA | MAIA Biotechnology, Inc. | $84.56M | Micro cap | −15.76% |
| VRCA | Verrica Pharmaceuticals Inc. | $84.35M | Micro cap | −13.25% |
| 0QW5.L | Heidelberg Pharma AG | $84.14M | Micro cap | −33.15% |
| CTOR | Citius Oncology, Inc. | $83.24M | Micro cap | −62.34% |
| POLB.L | Poolbeg Pharma PLC | $82.41M | Micro cap | +164.62% |
| 4888.T | Stella Pharma Corporation | $80.24M | Micro cap | −11.75% |
| ELTX | Elicio Therapeutics, Inc. | $78.32M | Micro cap | −71.29% |
| APLM | Apollomics, Inc. | $76.75M | Micro cap | +320.55% |
| OSTX | OS Therapies Incorporated | $76.68M | Micro cap | −34.00% |
| CRDF | Cardiff Oncology, Inc. | $76.56M | Micro cap | −54.65% |
| PLRX | Pliant Therapeutics, Inc. | $73.69M | Micro cap | −31.36% |
| XBIT | XBiotech Inc. | $70.43M | Micro cap | −33.62% |
| PMVP | PMV Pharmaceuticals, Inc. | $70.03M | Micro cap | −7.75% |
| RNXT | RenovoRx, Inc. | $67.24M | Micro cap | +61.08% |
| BOLD | Boundless Bio, Inc. | $66.31M | Micro cap | +155.70% |
| MAAT.PA | MaaT Pharma SA | $65.60M | Micro cap | −33.91% |
| XLO | Xilio Therapeutics, Inc. | $59.55M | Micro cap | −5.63% |
| HRTX | Heron Therapeutics, Inc. | $59.27M | Micro cap | −77.04% |
| 4564.T | OncoTherapy Science, Inc. | $56.36M | Micro cap | −25.00% |
| IMMP | Immutep Limited | $56.00M | Micro cap | −77.11% |
| 0OCQ.L | Transgene SA | $55.45M | Micro cap | −22.31% |
| ATX.AX | Amplia Therapeutics Limited | $54.23M | Micro cap | −14.71% |
| IMM.AX | Immutep Limited | $54.01M | Micro cap | −79.18% |
| 4572.T | Carna Biosciences, Inc. | $53.63M | Micro cap | +81.90% |
| TIL | Instil Bio, Inc. | $53.10M | Micro cap | −72.04% |
| 0RAD.L | OSE Immunotherapeutics SA | $51.87M | Micro cap | −48.50% |
| 4597.T | Solasia Pharma K.K. | $51.40M | Micro cap | −18.92% |
| CANTA.ST | Cantargia AB (publ) | $51.16M | Micro cap | −27.38% |
| PTX.AX | Prescient Therapeutics Limited | $50.63M | Micro cap | +63.41% |
| IBO | Impact BioMedical Inc. | $49.62M | Micro cap | −24.12% |
| COIL.L | Coiled Therapeutics plc | $49.30M | Micro cap | −26.92% |
| BKHA | Black Hawk Acquisition Corporation | $49.21M | Micro cap | +7.70% |
| SVE.WA | Synthaverse S.A. | $47.18M | Micro cap | −36.25% |
| 4594.T | BrightPath Biotherapeutics Co., Ltd. | $46.19M | Micro cap | −39.08% |
| MOC.WA | Molecure S.A. | $41.03M | Micro cap | −22.39% |
| CNTX | Context Therapeutics Inc. | $40.00M | Micro cap | −50.73% |
| 206A.T | PRISM BioLab Co.,LTD | $39.48M | Micro cap | −5.56% |
| SNT.AX | Syntara Limited | $38.09M | Micro cap | +1.89% |
| BCT.TO | BriaCell Therapeutics Corp. | $35.23M | Micro cap | −46.48% |
| BCTX | BriaCell Therapeutics Corp. | $35.06M | Micro cap | −46.97% |
| 190A.T | CHORDIA THERAPEUTICS INC | $33.98M | Micro cap | −59.32% |
| ATNM | Actinium Pharmaceuticals, Inc. | $31.69M | Micro cap | −42.61% |
| MDNA.TO | Medicenna Therapeutics Corp. | $31.26M | Micro cap | −56.48% |
| 4582.T | SymBio Pharmaceuticals Limited | $31.19M | Micro cap | −57.43% |
| BYSI | BeyondSpring Inc. | $28.37M | Micro cap | −62.09% |
| CVM | CEL-SCI Corporation | $28.32M | Micro cap | −87.65% |
| NNG.WA | NanoGroup S.A. | $28.00M | Micro cap | −17.36% |
| LTRN | Lantern Pharma Inc. | $27.87M | Micro cap | −46.17% |
| NXTC | NextCure, Inc. | $27.05M | Micro cap | +11.37% |
| EVAX | Evaxion A/S | $27.02M | Micro cap | +6.93% |
| PSTV | Plus Therapeutics Inc | $26.64M | Micro cap | −68.67% |
| ATOS | Atossa Therapeutics, Inc. | $26.45M | Micro cap | −76.75% |
| MRKR | Marker Therapeutics, Inc. | $24.18M | Micro cap | +54.26% |
| CLRB | Cellectar Biosciences, Inc. | $24.01M | Micro cap | −47.30% |
| CCM | Concord Medical Services Holdings Limited | $21.49M | Micro cap | −10.47% |
| ALLR | Allarity Therapeutics, Inc. | $21.32M | Micro cap | −15.72% |
| DEX.ST | Dextech Medical AB | $20.09M | Micro cap | +26.38% |
| NOX.AX | Noxopharm Limited | $19.87M | Micro cap | −10.00% |
| ALTME.PA | TME Pharma N.V. | $17.97M | Micro cap | +25.97% |
| TPST | Tempest Therapeutics, Inc. | $17.86M | Micro cap | −89.96% |
| AKTX | Akari Therapeutics, Plc | $17.72M | Micro cap | −72.42% |
| ABERA.ST | Abera Bioscience AB | $17.69M | Micro cap | +1.61% |
| B8FK.DE | Biofrontera AG | $17.36M | Micro cap | −3.07% |
| 4882.T | Perseus Proteomics Inc. | $17.25M | Micro cap | −56.56% |
| MDCX | Medicus Pharma Ltd. | $16.96M | Micro cap | −86.77% |
| RAD.AX | Radiopharm Theranostics Limited | $16.95M | Micro cap | −63.64% |
| CTXR | Citius Pharmaceuticals, Inc. | $16.57M | Micro cap | −57.88% |
| LSTA | Lisata Therapeutics, Inc. | $15.68M | Micro cap | −30.40% |
| INTS | Intensity Therapeutics, Inc. | $14.79M | Micro cap | −40.00% |
| ACTI.ST | Active Biotech AB (publ) | $14.50M | Micro cap | −62.00% |
| PHIO | Phio Pharmaceuticals Corp. | $13.94M | Micro cap | −40.89% |
| GTBP | GT Biopharma, Inc. | $13.52M | Micro cap | −74.55% |
| BLRX | BioLineRx Ltd. | $11.79M | Micro cap | −26.63% |
| TOVX | Theriva Biologics, Inc. | $11.16M | Micro cap | −42.10% |
| LNAI | Lunai Bioworks Inc. | $9.97M | Micro cap | −89.34% |
| PUR.WA | MultiQure S.A. | $9.70M | Micro cap | −55.05% |
| 4598.T | Delta-Fly Pharma, Inc. | $9.28M | Micro cap | −81.75% |
| IMNN | Imunon, Inc. | $9.15M | Micro cap | −73.10% |
| CNSP | CNS Pharmaceuticals, Inc. | $8.48M | Micro cap | −13.51% |
| AIM | AIM ImmunoTech Inc. | $7.61M | Micro cap | −89.69% |
| PAB.AX | Patrys Limited | $7.56M | Micro cap | −14.29% |
| BOLT | Bolt Biotherapeutics, Inc. | $7.55M | Micro cap | −26.73% |
| CANF | Can-Fite BioPharma Ltd. | $7.11M | Micro cap | −74.85% |
| ALOPM.PA | Oncodesign Precision Medicine Société anonyme | $7.05M | Micro cap | −19.44% |
| CHOSA.ST | Chosa Oncology AB | $7.01M | Micro cap | −9.00% |
| ITOC | iTonic Holdings Ltd. | $6.75M | Micro cap | −59.75% |
| NCNA | NuCana plc | $6.37M | Micro cap | −52.78% |
| LIMN | Liminatus Pharma, Inc. | $6.19M | Micro cap | +46.03% |
| PCSA | Processa Pharmaceuticals, Inc. | $5.95M | Micro cap | −60.00% |
| KAPA | Kairos Pharma, Ltd. | $5.88M | Micro cap | −77.97% |
| NFX.L | Nuformix plc | $5.85M | Micro cap | +80.68% |
| 0GP7.L | Medivir AB (publ) | $5.78M | Micro cap | +1.60% |
| PER.AX | PERCHERON FPO [PER] | $5.45M | Micro cap | −54.55% |
| BCAB | BioAtla, Inc. | $5.20M | Micro cap | −86.04% |
| HCWB | HCW Biologics Inc. | $4.96M | Micro cap | −55.15% |
| APS.TO | Aptose Biosciences Inc | $4.41M | Micro cap | +50.00% |
| OSRH | OSR Health, Inc. | $4.09M | Micro cap | −80.93% |
| RDHL | RedHill Biopharma Ltd. | $3.74M | Micro cap | −53.74% |
| DBP-B.ST | Double Bond Pharmaceutical International AB (publ) | $3.53M | Micro cap | +11.79% |
| CLDI | Calidi Biotherapeutics, Inc. | $3.49M | Micro cap | −19.16% |
| GOVX | GeoVax Labs, Inc. | $3.34M | Micro cap | −96.67% |
| ARTL | Artelo Biosciences, Inc. | $3.27M | Micro cap | −97.37% |
| IVX.AX | Invion Limited | $2.83M | Micro cap | −72.31% |
| PPBT | Purple Biotech Ltd | $2.81M | Micro cap | −92.21% |
| VAL.L | ValiRx plc | $2.78M | Micro cap | −73.04% |
| NXTS | Nexentis Technologies Inc. | $2.73M | Micro cap | −96.40% |
| PPCB | Propanc Biopharma, Inc. | $2.44M | Micro cap | −98.54% |
| NX1.AX | Nexalis Therapeutics Limited | $2.00M | Micro cap | −50.00% |
| PTP.DE | Pentixapharm Holding AG | $1.06M | Micro cap | +5.47% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.